Acrivon Therapeutics, Inc. (ACRV)Healthcare | Biotechnology | Watertown, United States | NasdaqGM
1.64 USD
-0.12
(-6.818%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 1.62 -0.02 (-0.020%) ⇩ (Oct. 16, 2026, 7:07 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:07 a.m. EDT
The immediate outlook is clouded by a sharp recent decline; the stock has fallen roughly 73% over the last two years, with the most recent annual period showing a massive drop. While the price has stabilized slightly in the last two weeks, the momentum remains fragile, and the statistical forecast offers no directional edge. Fundamentally, the picture is stark: the company is burning significant cash with negative operating and free cash flows, and it has failed to generate earnings for the trailing twelve months. The balance sheet, while currently bolstered by a large cash pile relative to debt, cannot sustain this burn rate indefinitely without further dilution or capital raises. Analyst sentiment is aggressively optimistic, projecting a target price nearly six times the current level, but this appears to be a speculative bet on a future clinical catalyst rather than a reflection of current operational reality. With no dividend to provide income and a business model that relies entirely on future success to validate its current valuation, the investment case is highly precarious. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.172759 |
| AutoTheta | 0.189818 |
| AutoETS | 0.190110 |
| AutoARIMA | 0.190113 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 4.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.125 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.44 |
| Market Cap | 70,279,512 |
| Forward P/E | -1.00 |
| Beta | 1.93 |
| Website | https://acrivon.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.027624309 |
| Address1 | 480 Arsenal Way |
| Address2 | Suite 100 |
| All Time High | 25.47 |
| All Time Low | 1.05 |
| Ask | 2.06 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 260,720 |
| Average Daily Volume3 Month | 318,214 |
| Average Volume | 318,214 |
| Average Volume10Days | 260,720 |
| Beta | 1.925 |
| Bid | 1.14 |
| Bid Size | 2 |
| Book Value | 2.023 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.64 |
| Current Ratio | 7.993 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.77 |
| Day Low | 1.63 |
| Debt To Equity | 2.44 |
| Display Name | Acrivon Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -76,875,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.228 |
| Enterprise Value | -17,564,486 |
| Eps Current Year | -1.816 |
| Eps Forward | -1.64167 |
| Eps Trailing Twelve Months | -1.88 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9782 |
| Fifty Day Average Change | -0.33819997 |
| Fifty Day Average Change Percent | -0.1709635 |
| Fifty Two Week Change Percent | -2.762431 |
| Fifty Two Week High | 3.56 |
| Fifty Two Week High Change | -1.92 |
| Fifty Two Week High Change Percent | -0.53932583 |
| Fifty Two Week Low | 1.27 |
| Fifty Two Week Low Change | 0.37 |
| Fifty Two Week Low Change Percent | 0.2913386 |
| Fifty Two Week Range | 1.27 - 3.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,668,522,600,000 |
| Float Shares | 25,827,721 |
| Forward Eps | -1.64167 |
| Forward P E | -0.9989827 |
| Free Cashflow | -39,823,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 74 |
| Fullday Change | -0.13999999 |
| Fullday Change Percent | -7.9545445 |
| Fullday Price | 1.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15396 |
| Held Percent Institutions | 0.50337005 |
| Implied Shares Outstanding | 42,853,362 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-11-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts. |
| Long Name | Acrivon Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 70,279,512 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_652690313 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -74,225,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 88,277,925 |
| Number Of Analyst Opinions | 6 |
| Open | 1.75 |
| Operating Cashflow | -62,920,000 |
| Operating Margins | 0.0 |
| Phone | 617 207 8979 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -1.219511 |
| Post Market Price | 1.62 |
| Post Market Time | 1,792,192,079 |
| Previous Close | 1.76 |
| Price Eps Current Year | -0.9030837 |
| Price Hint | 4 |
| Price To Book | 0.81067723 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.859 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -6.81818 |
| Regular Market Day High | 1.77 |
| Regular Market Day Low | 1.63 |
| Regular Market Day Range | 1.63 - 1.77 |
| Regular Market Open | 1.75 |
| Regular Market Previous Close | 1.76 |
| Regular Market Price | 1.64 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 261,578 |
| Return On Assets | -0.38019 |
| Return On Equity | -0.64627 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 42,853,362 |
| Shares Percent Shares Out | 0.0377 |
| Shares Short | 1,616,727 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,139,237 |
| Short Name | Acrivon Therapeutics, Inc. |
| Short Percent Of Float | 0.0563 |
| Short Ratio | 5.3 |
| Source Interval | 15 |
| State | MA |
| Symbol | ACRV |
| Target High Price | 19.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 11.5 |
| Target Median Price | 10.5 |
| Total Cash | 89,959,000 |
| Total Cash Per Share | 2.099 |
| Total Debt | 2,115,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.79455 |
| Two Hundred Day Average Change | -0.15454996 |
| Two Hundred Day Average Change Percent | -0.08612185 |
| Type Disp | Equity |
| Volume | 261,578 |
| Website | https://acrivon.com |
| Zip | 2,472 |